[go: up one dir, main page]

ZA9711719B - Use of 2-(3,4-dimethoxycinnamoyl)aminobenzoic acid for the manufacture of a medicament for the treatment or prevention of restenosis. - Google Patents

Use of 2-(3,4-dimethoxycinnamoyl)aminobenzoic acid for the manufacture of a medicament for the treatment or prevention of restenosis.

Info

Publication number
ZA9711719B
ZA9711719B ZA9711719A ZA9711719A ZA9711719B ZA 9711719 B ZA9711719 B ZA 9711719B ZA 9711719 A ZA9711719 A ZA 9711719A ZA 9711719 A ZA9711719 A ZA 9711719A ZA 9711719 B ZA9711719 B ZA 9711719B
Authority
ZA
South Africa
Prior art keywords
dimethoxycinnamoyl
restenosis
medicament
prevention
manufacture
Prior art date
Application number
ZA9711719A
Other languages
English (en)
Inventor
Juichi Fukuyama
Keiji Miyazawa
Shuichiro Hamano
Arao Ujiie
Original Assignee
Kissei Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25101171&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA9711719(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kissei Pharmaceutical filed Critical Kissei Pharmaceutical
Publication of ZA9711719B publication Critical patent/ZA9711719B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/606—Salicylic acid; Derivatives thereof having amino groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ZA9711719A 1996-12-30 1997-12-30 Use of 2-(3,4-dimethoxycinnamoyl)aminobenzoic acid for the manufacture of a medicament for the treatment or prevention of restenosis. ZA9711719B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/774,418 US6019104A (en) 1996-12-30 1996-12-30 Method for the treatment or prevention of restenosis associated with coronary intervention

Publications (1)

Publication Number Publication Date
ZA9711719B true ZA9711719B (en) 1998-06-25

Family

ID=25101171

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9711719A ZA9711719B (en) 1996-12-30 1997-12-30 Use of 2-(3,4-dimethoxycinnamoyl)aminobenzoic acid for the manufacture of a medicament for the treatment or prevention of restenosis.

Country Status (19)

Country Link
US (1) US6019104A (fr)
EP (1) EP0891185A2 (fr)
KR (1) KR19990087396A (fr)
CN (1) CN1220599A (fr)
AR (1) AR009446A1 (fr)
AU (1) AU7854198A (fr)
BR (1) BR9707877A (fr)
CA (1) CA2247306A1 (fr)
CZ (1) CZ251198A3 (fr)
EA (1) EA001931B1 (fr)
HU (1) HUP9904029A3 (fr)
ID (1) ID20165A (fr)
IL (1) IL125660A0 (fr)
NO (1) NO983947D0 (fr)
NZ (1) NZ331338A (fr)
PE (1) PE27399A1 (fr)
TR (1) TR199801698T1 (fr)
WO (1) WO1998029104A2 (fr)
ZA (1) ZA9711719B (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE358456T1 (de) * 1998-05-05 2007-04-15 Boston Scient Ltd Stent mit glatten enden
MXPA01007835A (es) * 1999-02-03 2002-04-24 Smithkline Beecham Corp Metodo para la prevencion o la reduccion de los eventos cardiovasculares asociados con la intervencion coronaria.
MXPA01007833A (es) * 1999-02-03 2002-06-21 Smithkline Beecham Corp Metodo para prevenir o reducir eventos cardiovasculares asociados con intervencion de la arteria coronaria.
AU2001243248A1 (en) * 2000-02-23 2001-09-03 Smith Kline Beecham Corporation Method for the prevention or reduction of vascular access dysfunction
US20050106230A1 (en) * 2003-11-17 2005-05-19 Young Janel E. Drug-enhanced adhesion prevention

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4070484A (en) * 1973-01-18 1978-01-24 Kissei Pharmaceutical Co., Ltd. Antiallergic composition containing aromatic carboxylic amide derivatives and method of using the same
JPS5640710B2 (fr) * 1973-01-18 1981-09-22
US4337270A (en) * 1980-05-21 1982-06-29 Hisamitsu Pharmaceutical Co., Inc. Novel anthranilic acid derivatives
JP2617407B2 (ja) * 1992-09-14 1997-06-04 キッセイ薬品工業株式会社 血管内膜細胞過剰増殖疾患の予防および治療剤

Also Published As

Publication number Publication date
HUP9904029A3 (en) 2000-11-28
IL125660A0 (en) 1999-04-11
EA199800781A1 (ru) 1999-12-29
WO1998029104A2 (fr) 1998-07-09
HUP9904029A2 (hu) 2000-05-28
NZ331338A (en) 2000-12-22
PE27399A1 (es) 1999-03-31
EP0891185A2 (fr) 1999-01-20
KR19990087396A (ko) 1999-12-27
AR009446A1 (es) 2000-04-12
US6019104A (en) 2000-02-01
BR9707877A (pt) 1999-07-27
WO1998029104A3 (fr) 1998-10-01
CZ251198A3 (cs) 1999-08-11
TR199801698T1 (xx) 1999-03-22
ID20165A (id) 1998-10-15
AU7854198A (en) 1998-07-31
CN1220599A (zh) 1999-06-23
EA001931B1 (ru) 2001-10-22
NO983947D0 (no) 1998-08-27
CA2247306A1 (fr) 1998-07-09

Similar Documents

Publication Publication Date Title
DE69310065D1 (de) Verwendung von 2-(3,4-Dimethoxycinnamoyl)aminobenzoesäure zur Herstellung eines Arzeimittels zur Behandlung der Restenose
IL127714A0 (en) Use of topiramate or derivatives thereof for the manufacture of a medicament for the treatment of manic depressive bipolar disorders
EP0664690A4 (fr) Pansement reutilisable en deux parties.
YU34199A (sh) Primena inhibitora gastrointestinalne lipaze
ZA9811629B (en) The use of MMP inhibitors for the treatment of ocular angiogenesis.
ZA977310B (en) Transdermal propentofylline compositions for the treatment of Alzheimer's disease.
AU6682298A (en) Use of r-nsaid's for the prevention of alzheimer's disease
ZA995444B (en) A method for the treatment of staphylococcal disease.
AU3728095A (en) Use of zaprinast for the manufacture of a medicament for inhibiting vascular restenosis
AU5038299A (en) Process for the biocidal treatment of surfaces
ZA9711719B (en) Use of 2-(3,4-dimethoxycinnamoyl)aminobenzoic acid for the manufacture of a medicament for the treatment or prevention of restenosis.
AU7982098A (en) Use of beta2-adrenoceptor agonists for the manufacture of a medicament for the treatment of scoliosis
AU2922792A (en) Method for treatment of a contact body for exchange of heat, moisture or the like
HUP9800334A3 (en) Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of obesity
ZA200110539B (en) Oxazinocarbazoles for the treatment of CNS diseases.
HK1018005A (en) Use of 2-(3,4-dimethoxycinnamoyl) aminobenzoic acid for the manufacture of a medicament for the treatment or prevention of restenosis
SI0778025T1 (en) Use of 8,9-dehydroestrone for the manufacture of a medicament for the treatment of diseases caused by free radicals
WO2001019358A3 (fr) Compositions pharmaceutiques destinees au traitement du psoriasis
CA2057456A1 (fr) Produit pharmaceutique contre la depression
AU3071899A (en) Use of pkc-inhibitors for the manufacture of a medicament for the treatment of asthma
ZA9610761B (en) Medical treatment.
IL123422A (en) USE OF 7alpha-METHYL-17alpha-ETHYNYL-ESTRANE DERIVATIVES FOR THE MANUFACTURE OF A MEDICAMENT FOR THE PROPHYLAXIS OR THE TREATMENT OF ATHEROSCLEROSIS
YU17002A (sh) Upotreba deksrazoksana u lečenju psorijaze
EP0579077A3 (en) 1,3,4-thiadiazinones for the treatment of cardiovascular diseases
FR2729861B3 (fr) Catheter, notamment pour l'endoscopie des voies biliaires